Zhu Quing, Tannenbaum Susan, Hegde Poornima, Kane Mark, Xu Chen, Kurtzman Scott H
Bioengineering Program, Electrical and Computer Engineering Department, University of Connecticut, 371 Fairfield Rd, U2157, Storrs, CT 06269, USA.
Neoplasia. 2008 Oct;10(10):1028-40. doi: 10.1593/neo.08602.
The purposes of this study were 1) to investigate the feasibility of using optical tomography in the near-infrared (NIR) spectrum combined with ultrasound (US) localization (NIR/US) in monitoring tumor vascular changes and assessing tumor pathological response during chemotherapy and 2) to compare the accuracy of NIR/US with magnetic resonance imaging (MRI) in predicting residual cancer after neoadjuvant chemotherapy. Eleven female patients were studied during treatments with a combined imager consisting of a commercially available US system coupled to an NIR imager. Contrast-enhanced MRI was performed before treatment and surgery. Tumor vascular content was assessed based on total hemoglobin concentration and volume obtained from NIR data. A percentage blood volume index (%BVI) was calculated as the percentage ratio of the product of total hemoglobin concentration and volume normalized to pretreatment values. At treatment completion, pathologic assessment revealed three response groups: complete or near-complete responders (A), partial responders (B), and nonresponders (C). The mean %BVIs of groups A, B, and C at the treatment completion were 29.1 +/- 6.9%, 46.3 +/- 3.7%, and 86.8 +/- 30.1%, respectively (differences statistically significant, P < .04). At the end of cycle 2, the %BVI of group A was noticeably lower than that of the partial (P = .091) and nonresponder groups (P = .075). Both NIR/US and MRI were equally effective in distinguishing different response groups in this pilot study. Our initial findings indicate that NIR/US using %BVI can be used during chemotherapy to repeatedly monitor tumor vascular changes. NIR/US also may evaluate pathologic response during treatment allowing for tailoring therapies to response.
1）研究在化疗期间使用近红外（NIR）光谱光学断层扫描结合超声（US）定位（NIR/US）监测肿瘤血管变化并评估肿瘤病理反应的可行性；2）比较NIR/US与磁共振成像（MRI）在预测新辅助化疗后残留癌症方面的准确性。在治疗期间对11名女性患者进行了研究，使用的组合成像仪由一台市售的US系统与一台NIR成像仪耦合而成。在治疗前和手术前进行了对比增强MRI检查。根据从NIR数据获得的总血红蛋白浓度和体积评估肿瘤血管含量。计算百分比血容量指数（%BVI），即总血红蛋白浓度与体积的乘积相对于治疗前值归一化后的百分比比率。治疗结束时，病理评估显示有三个反应组：完全或接近完全反应者（A组）、部分反应者（B组）和无反应者（C组）。治疗结束时A、B和C组的平均%BVI分别为29.1±6.9%、46.3±3.7%和86.8±30.1%（差异有统计学意义，P<.04）。在第2周期结束时，A组的%BVI明显低于部分反应组（P=.091）和无反应组（P=.075）。在这项初步研究中，NIR/US和MRI在区分不同反应组方面同样有效。我们的初步研究结果表明，使用%BVI的NIR/US可在化疗期间用于反复监测肿瘤血管变化。NIR/US还可在治疗期间评估病理反应，以便根据反应调整治疗方案。
